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Previewssufficient to induce singing in decapitated
males and females (Clyne and Miesen-
bo¨ck, 2008). Indeed, while dPR1 is male-
specific, vPR6 and vMS11 are present in
both sexes, albeit exhibiting sexually
dimorphic arborizations within the wing
neuropil. Furthermore, the impact of
vPR6 on pulse song patterning suggests
these neurons are a ‘‘mutable’’ part of
the song generator that might account
for the diversity in courtship serenades
critical for species recognition (Murthy,
2010).
While physiological evidence for func-
tional connections between P1, pIP10,
and the thoracic FruM neurons awaits,
von Philipsborn et al. (2011) assess over-
lap between axonal and dendritic arbors
of these neural classes to predict poten-
tial synaptic contacts. Their observations
suggest—though do not prove—that
these neurons are likely to form an inter-
connected circuit.
Together, these studies provide us with
an excellent—though incomplete—neural
framework to understand how converging
sensory inputs are interpreted to induce
a selection between alternative behavioral
outputs. The available data point to the
P1 cluster as the critical central neuronsthat trigger singing (and other aspects of
the courtship routine), but how might
these neurons weigh up positive and
negative sensory influences on the deci-
sion to initiate courtship? A hint is offered
by finer-scale thermal activation experi-
ments of von Philipsborn et al. (2011),
who found that at least ten out of 20 indi-
vidual P1 neurons must express TrpA1 to
induce singing. While it is unknown
whether these cells are functionally
homogeneous, it is intriguing to speculate
that attainment of this threshold number
of activated P1 neurons in wild-type
flies may be what tips the balance in
their mind in favor of courting. Future
high-resolution anatomical mapping and
physiological characterization of excit-
atory and inhibitory synaptic inputs to
these neurons from different sensory
systems, as well as their precise output
pathways may reveal the cellular mecha-
nisms by which neural circuits make
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In this issue of Neuron, Zhang et al. show that Synaptotagmin 4 (Syt4) is specifically induced in adult hypo-
thalamic oxytocin neurons by high-fat diet. Evidence is provided to support a critical role for Syt4 in negative
regulation of oxytocin release, which in turn is responsible for diet-induced obesity, raising the possibility of
using Syt4 as a new antiobesity target.Given the increasing prevalence of
obesity and the devastating comorbidities
associated with obesity, identifying effec-
tive antiobesity strategies is more impera-
tive than ever. Although the underlying
causes of the obesity epidemic are multi-
factorial, exposure to high-caloric diet(Western diet) is thought to be one of the
major reasons. In order to mimic human
obesity in animal models, a widely ac-
cepted strategy involves inducing obesity
in rodent models with high-fat diet (HFD)
feeding. The HFD feeding can induce
obesity and metabolic disorders in ro-dents that resemble the human metabolic
syndrome (Buettner et al., 2007). Thus,
important antiobesity drug targets can
be identified with HFD-induced obesity
models.
Research efforts in the last decades
have established that the hypothalamusFebruary 10, 2011 ª2011 Elsevier Inc. 401
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Previewsplays a central role in body weight regula-
tion. The hypothalamus contains diverse
groups of bodyweight-regulating neurons
that release distinct neurotransmitters,
the most studied of which are neuropep-
tides (Elmquist et al., 2005). Recent
evidence suggests that the oxytocin-
releasing neurons, located in the paraven-
tricular hypothalamus (PVH) and the
supraoptic nucleus, are implicated in
body weight regulation in addition to their
well-established role in social cognition
(Donaldson and Young, 2008). Reduced
oxytocin expression has been associated
with mouse models of obesity (Kublaoui
et al., 2008); pharmacological studies
demonstrate that oxytocin inhibits feed-
ing involving a projection from the PVH
to the hindbrain, where meal size is regu-
lated (Blevins et al., 2004), and, anatomi-
cally, oxytocin neurons express important
body weight regulators including Fto,
a prominent obesity-associated gene
identified in human genetic studies (Ols-
zewski et al., 2009). However, it is un-
known whether dysfunction in oxytocin
neurons contributes to the pathogenesis
of HFD-induced obesity.
Although the mechanisms underlying
hypothalamic neuropeptides in the regu-
lation of body weight remain to be estab-
lished, it has been commonly thought that
the rate of neuropeptide release corre-
lates with the expression level of the
peptide and with neuronal activity. This
is because neurons are equipped with
sophisticated but relatively rigid secretory
machinery that is responsible for a series
of events, which lead to neurotransmitter
release (Pang and Su¨dhof, 2010). One
key event in this process involves Ca2+-
triggered vesicle fusion with the presyn-
aptic membrane mediated by the fusion
complex. Synaptotagmin, a key compo-
nent of the fusion complex, senses Ca2+
and triggers final fusion pore formation
(Pang and Su¨dhof, 2010). Interestingly,
within the synaptotagmin family, the
mammalian synaptotagmin 4 (Syt4) is
atypical in that it is insensitive to Ca2+
but still capable of participating in the
fusion complex. Although controversy
exists regarding the action of Syt4 on
synaptic release, strong data support
that Syt4 reduces synaptic release,
presumably by decreasing the frequency
of fusion events owing to its inability to
sense Ca2+ influx (Littleton et al., 1999).402 Neuron 69, February 10, 2011 ª2011 ElsNevertheless, apart from an involvement
in regulating hippocampal brain-derived
neurotrophic factor (BDNF) release
(Dean et al., 2009), the physiological func-
tion of Syt4 remains largely unknown.
In this issue of Neuron, Zhang et al.
(2011) provide a strong case for the role
of Syt4 in the pathogenesis of HFD-
induced obesity through the regulation
of oxytocin release. In an effort to identify
potential regulators for neuropeptide
release, Zhang et al. (2011) noticed that
Syt4 is enriched in adult hypothalamic
neurons. Of interest, HFD feeding upregu-
lates Syt4 expression specifically in the
hypothalamus, suggesting a possible
role of Syt4 in HFD-induced obesity. To
test this possibility, they exposed Syt4
deficient syt4/ mice to HFD. On normal
chow diet, syt4/ mice exhibit a grossly
normal phenotype, suggesting a permis-
sive role for Syt4 under normal conditions.
However, when challenged by HFD,
syt4/ mice are completely protected
from HFD-induced obesity because of
reduced caloric intake and increased
energy expenditure. To ascertain the role
of hypothalamic Syt4 in obesity regula-
tion, the authors elegantly used shRNA-
mediated knockdown of Syt4 to specifi-
cally reduce Syt4 expression in the
hypothalamus. Results show that Syt4
knockdown protects mice against HFD-
induced obesity. Collectively, these data
demonstrate that the expression of hypo-
thalamic Syt4 is required for the manifes-
tation of HFD-induced obesity.
To reveal the identity of neurons that
mediate Syt4 function, Zhang et al. (2011)
examined the colocalization of Syt4 with
known hypothalamic neuropeptides.
Interestingly, Syt4 is exclusively localized
with oxytocin, but not found in nearby argi-
nine vasopressin (AVP) neurons. Further
electron microscopic studies revealed
that Syt4 is expressed in both dense and
small vesicles located in axonal terminals
and dendrites. The expression in axonal
terminals may reflect a role of Syt4 in
modulating Ca2+-induced vesicle fusion
in the posterior pituitary (Zhang et al.,
2009). The expression in dendrites is
consistent with dendritic release of
oxytocin. Thus, it appears that oxytocin
neurons mediate the effect of Syt4.
Is Syt4 expression in oxytocin neurons
sufficient to render an obesogenic effect?
To test this, Zhang et al. (2011) usedevier Inc.a combination of a viral vector and the
oxytocin promoter to overexpress Syt4
specifically in oxytocin neurons of wild-
type and syt4/ mice. In both cases,
overexpression leads to body weight
gain associated with higher food intake,
suggesting that the expression of Syt4 in
oxytocin neurons is sufficient for the
development of obesity. Interestingly,
the obesity associated with Syt4 overex-
pression is abrogated by pharmacolog-
ical application of oxytocin, suggesting
that the obesogenic action of Syt4 is
mediated by oxytocin. If this is the case,
as reflected by an earlier study showing
that Syt4 diminishes BDNF release
(Dean et al., 2009), then expression of
Syt4 should reduce oxytocin release.
Indeed, oxytocin release is increased
from syt4/ PVH slices relative to wild-
type mice under both basal and KCl-
evoked conditions. Consistently, com-
pared to wild-type mice, the serum
oxytocin levels in syt4/mice are almost
doubled on chow diet and tripled on HFD.
This dramatic increase in the oxytocin
level is due to specific deletion of Syt4 in
oxytocin neurons since this effect is abro-
gated by the overexpression of Syt4
specifically in these neurons. These re-
sults demonstrate that Syt4 profoundly
and specifically diminishes oxytocin
release, which represents a novel mecha-
nism by which hypothalamic neurons
regulate body weight.
Is the increased oxytocin release
responsible for the complete protection
from HFD-induced obesity in syt4/
mice? To investigate this, Zhang et al.
(2011) blocked the action of oxytocin in
syt4/ mice by either applying the
oxytocin receptor antagonist ornithine
vasotocin (OVT), or by knocking down
oxytocin expression in the PVH. In both
cases, the antiobesity effect of Syt4 defi-
ciency is diminished, thereby suggesting
that the augmented oxytocin action is
required for resistance to HFD-induced
obesity in syt4/ mice. This result is
corroborated by the effect of oxytocin on
preventing HFD-induced obesity pre-
sentedby theauthorsand theanorexigenic
effect of oxytocin previously reported by
others (Blevins et al., 2004; Kublaoui
et al., 2008). One prediction based on
these results is that mice with oxytocin
deficiency will be more sensitive to HFD-
induced obesity, which is yet to be tested.
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PreviewsHowdoesHFD upregulate Syt4 expres-
sion in oxytocin neurons? Syt4 expression
can be induced by increased neuron
activity and intracellular cyclic AMP
(cAMP) (Vician et al., 1995). One might
speculate that the Syt4 induction is medi-
ated by the melanocortin receptor 4
(MC4R), a critical regulator for body
weight homeostasis. This speculation is
supported by the increased MC4R that
has been observed in the PVH upon
HFD feeding (Enriori et al., 2007), which
is thought to be coupled with increased
cAMP. Is oxytocin the only mediator for
the resistance to HFD-induced obesity in
syt4/ mice? Both pharmacological
blockage of oxytocin action and knock-
down of oxytocin expression in syt4/
mice only partially reversed the antiobe-
sity effect by Syt4 deficiency. This result
may indicate a role for additional neuro-
transmitters from oxytocin neurons
although technical limitations could also
underlie the partial effects. Given the
association of Syt4 with small vesicles,
the release of neurotransmitters con-
tained in small vesicles will also be simi-
larly affected by Syt4 deficiency. In this
regard, oxytocin neurons are glutamater-
gic and whether glutamate release medi-
ates antiobesity effect by Syt4 deficiency
should also be an interesting future study.
In addition, according to the Alan Brain
Atlas gene expression database, Syt4 is
expressed in a subset of hindbrain
neurons, a brain site also heavily involved
in feeding and body weight regulation.
Whether Syt4 is similarly induced in these
areas by HFD and whether these neurons
contribute to the antiobesity function of
Syt4 deficiency await further studies.
Mechanistically, it remains to be estab-
lished how increased Syt4 leads to
reduced oxytocin release. Notably, it
appears that the dramatic increase in
oxytocin release by Syt4 deficiency can’t
entirely be explained by the previous
observation that in syt4/ mice, low
Ca2+ entry triggers more release whilehigh Ca2+ entry triggers less release
from axon terminals of the posterior pitui-
tary (Zhang et al., 2009). These axon
terminals are presumably from oxytocin
neurons since only oxytocin and AVP
neurons send projections to the posterior
pituitary and Syt4 is not expressed in AVP
neurons. The reason for this discrepancy
is unknown but may involve different
approaches used in the two studies (elec-
trophysioligical recordings versus peptide
release assay). In light of Syt4 localization
in vesicles, the ability of Syt4 to form the
fusion complex, and the inability to sense
Ca2+, it can be hypothesized that the
increased Syt4 prevents Ca2+-mediated
vesicle exocytosis as previously demon-
strated (Littleton et al., 1999).
Can Syt4 be an effective antiobesity
drug target? Although more proof of
concept studies are required before tar-
geting Syt4 for obesity treatment, the
following functional characteristics of
Syt4 provided by Zhang et al. (2011) argue
that it could be an attractive drug target
for the current obesity epidemic: (1)
permissive role of Syt4 at the basal level
(i.e., on chow diet); (2) abundant Syt4
only found in a few brain sites in adult
mice; (3) specific induction of Syt4 in
oxytocin neurons by HFD and (4) robust
effects of Syt4 deficiency on the preven-
tion of HFD-induced obesity. These char-
acteristics should in principle form a basis
for developing effective antiobesity drugs.
In sum, the study by Zhang et al. (2011)
nicely bridges the gap in our under-
standing of the physiological function of
Syt4 and the mechanism of HFD-induced
obesity. The authors employed an elegant
combination of mouse genetics, RNA
interference, stereotaxic injection, and
viral-directed expression approaches,
and have provided comprehensive evi-
dence for an obesogenic oxytocin
neuron-specific program. This program
includes HFD-induced Syt4 expression,
reduced oxytocin release, increased
caloric intake, reduced energy expendi-Neuron 69,ture, and ultimately the manifestation of
obesity. This program represents a previ-
ously unknown mechanism for obesity
pathogenesis. Do other neuropeptide-
releasing neurons contribute to this novel
mechanism? More investigations stem-
ming from the findings by Zhang et al.
(2011) will answer this question in the
years to come.REFERENCES
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